NEW YORK, Jan. 7, 2013 /PRNewswire/ -- Allergan Inc. (NYSE: AGN $98) has been picked by S&P Capital IQ as its Focus Stock of the Week. AGN carries S&P Capital IQ's highest investment recommendation of 5-STARS, or Strong Buy. "We see solid growth prospects in Allergan's core Botox and ophthalmic pharmaceutical franchises, and an advancing pipeline that we expect to spawn multiple drivers over the coming years," said Herman Saftlas, equity analyst at S&P Capital IQ. "Unlike many big pharma players, we believe that most of the company's key franchises are valued proprietary brands with limited generic exposure." About S&P Capital IQ S&P Capital IQ, a business line of the McGraw-Hill Companies (NYSE:MHP), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. We provide a broad suite of capabilities designed to help track performance, generate alpha, identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Valuations, and Compustat; and research offerings, including Leveraged Commentary & Data, Global Market Intelligence, and company and fund research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit www.spcapitaliq.com. All information provided by S&P Capital IQ is impersonal and not tailored to the needs of any person, entity or group of persons. Past performance is no indication of future results. S&P Capital IQ and its affiliates provide a wide range of services to, or relating to, many organizations, including issuers of securities, investment advisers, broker-dealers, investment banks, other financial institutions and financial intermediaries, and accordingly may receive fees or other economic benefits from those organizations, including organizations whose securities or services they may recommend, rate, include in model portfolios, evaluate or otherwise address.